AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B Post published:August 25, 2025 Post category:Analysis/News/Pα+
Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression Post published:August 25, 2025 Post category:Analysis/News/Pα+
Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression Post published:August 18, 2025 Post category:Analysis/News/Pα+
One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect Post published:August 15, 2025 Post category:Analysis/Pα+
From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research Post published:August 12, 2025 Post category:Analysis/Interviews
Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches Post published:August 5, 2025 Post category:Analysis/Interviews/News/Pα+
Germany Establishes EU’s First Psilocybin Compassionate Access Program Post published:July 31, 2025 Post category:Analysis/News
Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2) Post published:July 29, 2025 Post category:Analysis/News
Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1) Post published:July 23, 2025 Post category:Analysis/News/Pα+